FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect-Reference-Cited by-同舟云学术

FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect

Published:2024-04-23 Issue:14 Volume:30 Page:2857-2859
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Raeder Henry W.¹^ORCID,Drazer Michael W.²³^ORCID

Affiliation:

1. Department of Human Genetics, University of Chicago, Chicago, Illinois. 1

2. Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois. 2

3. Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois. 3

Abstract

Summary Expansion of conventional dendritic cells via FMS-like tyrosine kinase 3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. In this study, we discuss the results of a clinical trial using GS-3583, an FMS-like tyrosine kinase 3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia. See related article by Tolcher et al., p. 2954

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-24-0460/3444701/ccr-24-0460.pdf

Reference17 articles.

1. Phase I study of GS-3583, an FMS-like tyrosine kinase 3 agonist Fc fusion protein, in patients with advanced solid tumors;Tolcher;Clin Cancer Res,2024

2. Genomic correlates of response to immune checkpoint blockade;Keenan;Nat Med,2019

3. FLT3 targeting in the modern era: from clonal selection to combination therapies;Kennedy;Int J Hematol,2023

4. GS-3583, a novel FLT3 agonist Fc fusion protein, to expand conventional dendritic cells in healthy volunteers;Nishanthan;J Clin Oncol,2021

5. Age-related clonal hematopoiesis associated with adverse outcomes;Jaiswal;N Engl J Med,2014